共查询到19条相似文献,搜索用时 109 毫秒
1.
目的探讨个体化激素治疗对更年期综合征患者生存质量的影响。方法选取2011年11月—2013年12月于该院就诊的124例更年期综合征女性作为该次研究的对象,将患者随机分为观察组和对照组两组,每组患者有62例。观察组患者采用激素补充治疗,对照组患者采用益贞女金片治疗。对比两组患者的治疗效果以及用药前后血脂、子宫内膜厚度、性激素测定。结果两组患者通过用药治疗后,其更年期症状都得到一定程度的改善,观察组的总有效率达到98.39%,对照组总有效率为79.03%,对比两组患者的治疗总有效率,差异有统计学意义(P<0.05)。观察组患者治疗前后的子宫内膜厚度无明显变化,血低密度脂蛋白与FSH要明显低于治疗前,高密度脂蛋白与E2要明显高于用药前,差异有统计学意义(P<0.05)。结论不同剂量的激素周期序贯治疗是依据每个女性对药物反应的差异制定而成,可以显著改善患者的更年期症状,有效调节患者的血清卵泡雌激素、雌二醇以及血脂水平,有效改善更年期女性的生活质量,值得在临床上大力推广。 相似文献
2.
目的 :探究在更年期综合征患者的临床治疗中激素治疗对患者的生存质量影响情况.方法 :2016年1月至2016年12月期间,我院妇科接受诊治的更年期综合征患者168例作为研究对象,结合患者接受诊治的挂号顺序进行分组,其中单号设定为对照组,双号设置为观察组,对照组患者未采用激素进行治疗,观察组患者则结合激素进行治疗,对比两组患者的生存质量改善情况.结果 :两组患者在治疗后其生存质量都有一定程度的改善,对照组和观察组治疗前评分为23.6分、23.7分,同时治疗后观察组患者的生存质量10.3分评分明显优于对照组18.2分,差异显著(P<0.05).结论 :在更年期综合征患者的临床治疗中应用激素进行治疗能够有效改善患者的生存质量,对妇女的更年期过渡有很好的保证,值得在临床治疗中推广应用. 相似文献
3.
激素治疗对更年期综合征妇女生活质量的影响 总被引:1,自引:0,他引:1
目的 观察个体化激素替代治疗对更年期综合征妇女生活质量的影响.方法 选择有明显绝经相关症状的更年期妇女52例,分为两组,其中用个体化激素治疗者(HRT组)22例,服用益贞女金片患者(女金片组)30例,分别于用药前及用药后3个月时采用改良Kapperman评分法评分.HRT组治疗前后进行子宫内膜厚度及血脂、性激素测定.结果 两组均能明显减轻患者的更年期症状,但女金片的作用明显次于HRT(P<0.05)治疗前后,HRT组患者血脂中低密度脂蛋白较用药前明显下降(P<0.05),高密度脂蛋白较用药前升高(P<0.05),促卵泡成熟激素(FSH)明显降低(P<0.05),血雌二醇(E2)明显高于治疗前(P<0.05),子宫内膜厚度无明显增厚(P>0.05).结论 根据个体对药物反应不同制定不同剂量的激素周期序贯方法,能明显减轻患者更年期症状,有效调节血FSH、E2及血脂水平,提高更年期妇女的生活质量. 相似文献
4.
5.
目的:了解激素替代治疗对更年期患者心理因素的影响。方法:对更年期门诊患者119例予以激素替代治疗,了解她们接受治疗与拒绝治疗的原因。结果:20%的患者愿意接受治疗,45%的患者拒绝治疗,恐癌心理普遍存在(妇科恶性肿瘤),25%的患者持顺其自然的心理状态,10%的患者对治疗无足够的认识。结论:激素替代治疗(HRT)药物的副作用及可能诱发的妇科恶性肿瘤对更年期妇女产生了较大的负面影响。 相似文献
6.
7.
8.
目的:了解更年期妇女月经改变、绝经相关症状发生时间,对激素补充治疗(HRT)的知晓、使用及相关知识需求情况,为中老年妇女生殖保健提供依据.方法:对年龄≥40岁、至少有一侧卵巢、有月经周期改变或更年期症状的妇女进行有关问卷调查.结果:共纳入326例妇女,平均年龄49.49岁,绝经年龄49.1岁,月经改变年龄45.6岁,出现更年期症状年龄46.6岁;38.6%知晓HRT的相关知识,44.2%认为更年期综合征有必要治疗,42.1%愿意接受HRT但有诸多担心顾虑,96.7%希望得到更多围绝经期保健知识;HRT使用率为5.83%.结论:更年期妇女对HRT与更年期保健知识的知晓率低,获取渠道主要为妇产科医生,应注重宣传教育,提供方便的医学支持服务,进一步提高中老年妇女的健康水平和生活质量. 相似文献
9.
目的探讨不同剂量激素补充对围绝经期妇女更年期综合征的影响。方法选取2011年6月-2012年6月永州市江华县人民医院收治的142例围绝经期妇女,分为低剂量组(91例)和常规剂量组(51例),分别给予0.3mg和0625mg雌激素治疗,观察两组治疗效果。结果两组患者更年期综合征改善情况比较,差异无统计学意义;低剂量组不良反应发生率低于常规剂量组,差异有统计学意义(P〈0.05)。结论低剂量激素补充疗法可有效改善围绝经期妇女更年期综合征症状,且安全性较好,值得临床推广应用。 相似文献
10.
11.
激素替代治疗更年期妇女80例分析 总被引:4,自引:0,他引:4
目的探讨小剂量激素治疗对绝经期症状的改善。方法将80例绝经期妇女(无激素替代治疗禁忌症)作为研究对象,其中40例作为治疗组,40例作为对照组,5年后比较治疗组和对照组产生的并发症及医疗开支。结果使用激素替代治疗组妇女出现骨质疏松、冠心病、老年性阴道炎、老年痴呆明显减小。结论小剂量激素替代治疗是更年期症状改善最佳方法,关键是掌握正确使用激素的要点,减少因激素使用不当产生的并发症。 相似文献
12.
Effects of hormone replacement therapy on platelet activation in postmenopausal women 总被引:1,自引:0,他引:1
Somestudieshavesuggestedthatestrogenplaysaprotectiveroleagainstatherosclerosiswithoutchangesinlipidlevels 1 Othershavedemonstratedthatestrogenisassociatedwiththehemostaticsystemandisabletopreventthrombogenesis ,whichmaymediatecardiovascularprotection 2 Ontheotherhand ,epidemiologicalstudieshaveshownthattherelativerisk (RR)ofvenousthrombogenesisandpulmonaryembolismsareincreasedinpostmenopausalwomenwhohavetakenHRT 3,4Plateletplayacrucialroleinthrombogenesis Itsfunctiondependsontheinteractio… 相似文献
13.
目的观察雌、孕激素连续联合用药对绝经后膝骨关节炎(OA)患者的疗效.方法将64例有放射学证据并有关节疼痛的绝经后膝关节OA患者(45~75岁)随机分为治疗组和对照组,分别给予每日口服戊酸雌二醇(E2V)1.0mg 安宫黄体酮(MPA)2 mg和安慰剂治疗,共6个月,所有患者均同时给予乳酸钙8片/d(相当于400mg元素钙).采用0~100mm目测模拟标尺线(VAS)方法,于用药前,用药1、3、6个月末对关节疼痛等症状程度进行评价.结果用药1个月时,治疗组患者和对照组患者在夜间睡眠痛和步行时疼痛方面的变化差异有显著性(P分别为0.036和0.035).用药6个月时,两组在夜间睡眠痛、步行时疼痛及晨僵持续时间改善程度方面相比,差异均有显著性(P分别为0.026、0.027和0.011).结论雌、孕激素连续联合补充治疗对绝经后膝OA患者的临床症状有一定缓解作用. 相似文献
14.
目的探讨绝经早期激素治疗对绝经妇女生活质量的影响。方法围绝经期妇女100例,根据药物应用的不同分为治疗组与对照组各50例,对照组给予利维爱治疗,治疗组给予雌激素联合孕激素应。结果两组治疗前FSH与E2含量对比无明显差异,治疗后治疗组E2含量明显升高,FSH明显下降(P〈0.05),组间比较差异有统计学意义(P〈0.05);两组患者在治疗前的SCL-90评分无明显差异(P〉0.05),而治疗后两组患者的SCL-90评分较治疗前均有明显升高(P均〈0.05);治疗后两组患者的SCL-90评分比较,差异有统计学意义(P〈0.05)。结论绝经早期激素治疗应用于妇女围绝经期能有效改善性激素水平,提高妇女的生活质量,值得推广应用。 相似文献
15.
长期小剂量性激素替代疗法对绝经后妇女骨密度的影响 总被引:1,自引:0,他引:1
目的观察长期应用小剂量性激素替代疗法对绝经后妇女骨密度及骨关节痛发生的影响。方法选择北京协和医院141名绝经后医护人员,分为性激素替代治疗(HRT)组(n=63)和对照组(n=78)。HRT组接受小剂量HRT5~32年,对照组年龄与HRT组匹配,未接受HRT。比较两组治疗后腰椎、WARD三角、股骨颈、股骨粗隆和全髋总骨密度及骨关节痛的发生率。结果HRT组L2-4的骨密度比对照组高9·1%(P<0·05)。HRT组和对照组骨关节痛的发生率分别为71·4%和89·7%,两组相比差异具有显著性(P<0·05)。结论长期小剂量HRT可减少绝经后妇女骨量丢失,降低骨关节痛发生。 相似文献
16.
Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine 总被引:8,自引:0,他引:8
Background To compare the efficacy and safety of hormone replacement therapy (HRT) combined with fluoxetine, with HRT alone, in post-menopausal women suffering from depression.Methods A randomized, open-label, parallel trial was applied. HRT was administered to all patients for 2 cycles, with 14 days of estrogen therapy and 14 days of estrogen plus progesterone. Patients who were randomly assigned to the HRT plus fluoxetine group were given fluoxetine in combinationwith HRT. Hamilton Depression Rating Scale (HAMD), Kupperman Menopausal Index (KMI), and Clinical Global Impressions scale were used to measure the efficacy.Results One hundred and twenty-three post-menopausal patients with depression were enrolled in the study. Among them, 120 had at least one post-treatment visit and entered into the statistical analysis. The mean total HAMD scores were significantly lower, and the percentages of HAMD score reductions were higher in the HRT plus fluoxetine Group compared with the HRT Group, after at least 3 weeks of treatment, with an average difference of 5 points at the endpoint. The Clinical Global Impression-Severity and Clinical Global Impression-Improvement scores were significantly different in the 2 groups, in favor of the combination therapy. The mean total KMI was significantly lower in the Combination Group compared with the HRT Group, after at least 6 weeks of treatment, with an average 4. 5-point difference between the groups. No statistically significant differences were found in most of the adverse events reported in the Combination Group compared with the HRT group, with the exception of 3 symptoms, i. e., dry mouth, loss of appetite, and abdominal distention. They were mild to moderate in severity. Two patients in the HRT group, but none in the combination group, dropped out due to adverse events.Conclusion HRT plus fluoxetine therapy was effectivewith a satisfactory safety profile.in the treatment of menopausal depression with a satisfactory safety profile. 相似文献
17.
Background To compare the efficacy and safety of hormone replacement therapy (HRT) combined with fluoxetine, with HRT alone, in post-menopausal women suffering from depression.Methods A randomized, open-label, parallel trial was applied. HRT was administered to all patients for 2 cycles, with ]4 days of estrogen therapy and 14 days of estrogen plus progesterone. Patients who were randomly assigned to the HRT plus fluoxetine group were given fluoxetine in combination with HRT. Hamilton Depression Rating Scale (HAMD), Kupperman Menopausal Index (KMI), and Clinical Global Impressions scale were used to measure the efficacy. Results One hundred and twenty-three post-menopausal patients with depression were enrolled in the study. Among them, 120 had at least one post-treatment visit and entered into the statistical analysis. The mean total HAMD scores were significantly lower, and the percentages of HAMD score reductions were higher in the HRT plus fluoxetine Group compared with the HRT Group, after at least 3 weeks of treatment, with an average difference of 5 points at the endpoint. The Clinical Global Impression-Severity and Clinical Global Impression-Improvement scores were significantly different in the 2 groups, in favor of the combination therapy. The mean total KMI was significantly lower in the Combination Group compared with the HRT Group, after at least 6 weeks of treatment, with an average 4. 5-point difference between the groups. No statistically significant differences were found in most of the adverse events reported in the Combination Group compared with the HRT group, with the exception of 3 symptoms, i. e., dry mouth, loss of appetite, and abdominal distention. They were mild to moderate in severity. Two patients in the HRT group, but none in the combination group, dropped out due to adverse events. Conclusion HRT plus fluoxetine therapy was effective in the treatment of menopausal depression with a satisfactory safety profile. 相似文献
18.
19.
目的:探讨小剂量激素替代(HRT)治疗对绝经早期妇女生理、心理健康的影响。方法:选择绝经早期有明显症状和不同程度心理症状的病人40例。每天口服倍美力0.3mg及安宫黄体酮片2mg,同时口服钙剂6个月,于治疗前后分别填写临床症状调查表和心理症状自评量表(SCL-90),比较用药前后临床症状和SCL-90各项指标的变化,做相关性分析;通过B超监测其安全性。结果:小剂量HRT治疗前后比较临床症状和SCL-90各项指标均有显著差异(P<0.05,P<0.01)。临床症状与心理症状存在相关性(P<0.01)。在治疗过程中子宫内膜未见增生。结论:小剂量HRT能安全、有效改善绝经早期妇女生理、心理相关症状,明显提高生活质量。 相似文献